Title: Role of Ultrafiltration in Peritoneal Dialysis: A Review
Author: Dr Ashok Kumar M.D (Medicine)
DOI: https://dx.doi.org/10.18535/jmscr/v5i5.213
References
1. Brown EA, Davies SJ, Rutherford P, et al. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14:2948–57.
2. Jansen MAM, Termorshuizen F, Korevaar JC, et al. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 2005; 68: 1199–205.
3. The European Best Practice Guideline Working Group on Peritoneal Dialysis: adequacy of peritoneal dialysis. Nephrol Dial Transplant 2005;20:ix24-ix27.
4. Lo WK, Bargman JM, Burkart J, et al. Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int 2006;26:520–522.
5. Davies SJ, et al. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11(3):498-506.
6. Prakash J, et al. Non-infectious complications of continuous ambulatory peritoneal dialysis and their impact on technique survival. Indian J Nephrol 2011;21:112-5.
7. Heimburger O, et al. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990;38(3): 495-506.
8. Mujais S, et al. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Evaluation and management of ultrafiltration problems in peritoneal dialysis. Perit Dial Int 2000;20(Suppl 4):S5-21.
9. Ho-dac-Pannekeet MM, et al. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 1997;17(2):144-150.
10. Smit W, et al. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study. Perit Dial Int 2004;24(6):562-570.
11. Kieran McCafferty and Stanley L.-S. Fan. Are we underestimating the problem of ultrafiltration In peritoneal dialysis patients? Perit Dial Int 2006; 26:349–352.
12. Agarwal DK, Sharma AP, Gupta A, et al. Peritoneal equilibration test in Indian patients on continuous ambulatory peritoneal dialysis: Does it affect patient outcome? Adv Perit Dial 16 : 148–151, 2000.
13. Mortier S, De Vriese AS, Lameire N. Recent concepts in the molecular biology of the peritoneal membrane-implications for more biocompatible dialysis solutions. Blood Purif 2003;21(1):14-23.
14. Williams JD, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13(2):470-479.
15. Yanez-Mo M, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003;348(5):403-413.
16. Aroeira LS, et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005;46(5):938-948.
17. Posthuma N, ter Weel PM, Donnker AJM, et al. Icodextrin use is CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations. Nephrol Dial Transplant 1998; 13: 2341–2344.
18. Monquil MC, et al. Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int 1995;15(1):42-48
19. Pannekeet MM, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995;48(3):866-875.
20. Rigby R, Hawley C. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154–9.
21. Nomoto Y, Kawaguchi Y, Kubo H, et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420–7.
22. Korte MR, Yo M, Betjes MG, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2002; 22:2412–14.
23. Kawanishi H, Kawaguchi Y, Fukui H, et al.; for the Long-Term Peritoneal Dialysis Study Group. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729–37.
24. Kawaguchi Y, et al. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. Perit Dial Int 2000;20(Suppl 4):S43-S55.
25. Balasubramaniam G, Brown EA, Davenport A, et al. Clinical course and management of encapsulating peritoneal sclerosis: a multicentre retrospective survey from the UK. Nephrol Dial Transplant 2009; 24:3209–15.
26. de Freitas DG, Augustine T, Brown EA, et al.; (UK EPS Group). Encapsulating peritoneal sclerosis following renal transplantation—the UK experience. Am J Transplant 2007; 7(Suppl 2):163.
27. Hawley CM, Wall DR, Johnson DW, et al. Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1995; 26:658–61.
28. Brown EA, van Biesen W, et al. ISPD Working Party. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int 2009; 29:595-600.
29. Bargman JM. New technologies in peritoneal dialysis. Clin J Am Soc Nephrol 2007;2(3):576-580.
30. Twardowski Z. Computerized tomography CT in the diagnosis of subcutaneous leak sites during continuous ambulatory peritoneal dialsis (CAPD). Perit Dial Bull 1984;4:163-166.
31. Kopecky RT, et al. Prospective peritoneal scintigraphy in patients beginning continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1990;15(3):228-236.
32. Smit W, et al. Peritoneal function and assessment of reference values using a 3.86% glucose solution. Perit Dial Int 2003;23(5):440-449.
33. Van Dijk CM, Ledesma SG, Teitelbaum I. Patient characteristics associated with defects of the peritoneal cavity boundary. Perit Dial Int 2005;25(4):367-373.
34. Leblanc M, Ouimet D, Pichette V. Dialysate leaks in peritoneal dialysis. Semin Dial 2001;14(1):50-54.
35. Juergensen PH, et al. Value of scintigraphy in chronic peritoneal dialysis patients. Kidney Int 1999;55(3):1111-1119.
36. Davies SJ, et al. Clinical evaluation of the peritoneal equilibration test: a population-based study. Nephrol Dial Transplant 1993;8(1):64-70.
37. Schleifer C. Migration of peritoneal catheters: personal experience and survey of 72 other units. Perit Dial Bull 1987;1987:189-193.
38. Warren PJ, Brandes JC. Compliance with the peritoneal dialysis prescription is poor. J Am Soc Nephrol 1994;4(8):1627-1629.
39. Brandes JC. Do we have an objective method to determine compliance with the peritoneal dialysis prescription? Perit Dial Int 1996;16(2):114-115.
40. Li PK, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003;139(2):105-112.
41. Suzuki H, et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004;43(6):1056-1064.
42. Lo WK, et al. Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int 2006;26(5):520-522.
43. Medcalfe JF, Harris KPG, Walls J. Frusemide increases urine volume but does not preserve residual renal function in patients on CAPD–results of a six months randomized controlled study. Perit Dial Int 1998; 18 (suppl. 2): S1.
44. van Olden RW, Guchelaar HJ, Struijk DG, et al. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int 2003; 23(4): 339–347.
45. Mujais S. Ultrafiltration management in automated peritoneal dialysis. In Ronco C, Amici G, Feriani M, Virga G (eds). Automated Peritoneal Dialysis, vol 129. Contrib Nephrol. Basel: Karger, 1999: 255–266.
46. Vargemezis V, Thodis E. Prevention and management of peritonitis and exit-site infection in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2001; 16 (suppl. 6): 106–108.
47. Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kindey Int 1996; 50: 979–986.
48. Peers E, Gokal R. Icodextrin: Overview of clinical experience. Perit Dial Int 1997; 17: 22–26.
49. Peers E, Gokal R. Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume. Artif Organs 1998; 22:8–12.
50. Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of technique survival. Perit Dial Int 1997; 17: 84–87.
51. , , , et al. Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature. Int Urol Nephrol. 2011; 43: 203–209.
52. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12:550–3.
53. Freida P, Galach M, Divino Filho JC, Werynski A, Lindholm B. Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long dwell. Perit Dial Int2007; 27:267 -76
54. Baranowska-Daca E, et al. Use of bethanechol chloride to increase available ultrafiltration in CAPD. Adv Perit Dial 1995;11:69-72.
55. Shah H, Chu M, Bargman JM. Perioperative management of peritoneal dialysis patients undergoing hernia surgery without the use of interim hemodialysis. Perit Dial Int 2006;26(6):684-687.
56. Moss JS, et al. Malpositioned peritoneal dialysis catheters: a critical reappraisal of correction by stiff-wire manipulation. Am J Kidney Dis 1990;15(4):305-308.
57. Crabtree JH. Selected best demonstrated practices in peritoneal dialysis access. Kidney Int Suppl 2006;70(103):S27-S37.